Investment analysts at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for shares of Quest ...

In a report released on April 2, Michael Cherny from Leerink Partners maintained a Buy rating on McKesson (MCK – Research Report), with a price ...

Leerink Partners analyst Faisal Khurshid reiterated a Hold rating on Nurix Therapeutics (NRIX – Research Report) on April 2. The company’s ...

Shares of Hims & Hers closed 5.1% higher after the company said it will expand its weight-loss offerings with branded ...

Fintel reports that on March 28, 2025, Leerink Partners downgraded their outlook for Equillium (NasdaqCM:EQ) from Outperform ...

Pharma’s reprieve from Donald Trump’s tariffs is expected to be temporary, with Leerink analysts anticipating possible sector ...

Leerink Partners upgraded shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) from a market perform rating to an outperform rating in a research report report published on Wednesday, MarketBeat ...

Fintel reports that on April 2, 2025, Leerink Partners upgraded their outlook for Compass Therapeutics (NasdaqCM:CMPX) from Market Perform to Outperform. As of March 19, 2025, the average one-year ...

SAN DIEGO, March 4, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ...

will present at the Leerink Partners Global Biopharma Conference in Miami, FL on Monday, March 10, 2025, at 3:00 p.m. ET. A live webcast of the presentation may be accessed via the Investors ...